Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SORCE adjuvant sorafenib versus placebo after resection of renal cell carcinoma
ISRCTN38934710Phase 3Completed
- Sponsor
- Medical Research Council
- Start
- Jun 2007
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial of sorafenib in renal cell carcinoma (RCC) (3 arms), sponsored by Medical Research Council. Primary endpoint: Disease-free survival. Started Jun 2007; status: completed.
02
Drugs
sorafenib
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on ISRCTN38934710.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN38934710.